Dynamics of expression rates of growth factor proteins in psoriatic patients receiving a phototherapy

Cover Page

Cite item


Goal. To study the dynamics of expression rates of growth factor proteins in psoriatic patients receiving the PUVA therapy. Materials and methods. The authors conducted a study of 30 patients with psoriasis vulgaris treated with the PUVA therapy. The psoriasis severity and extent of itching were assessed prior to and after the treatment by the PASI index and visual analogue scale, respectively. The expression of semaphorin 3A, amphiregulin, nerve growth factor and PGP 9.5 protein (a nerve fiber marker) in the skin was assessed by the indirect immunofluorescence method. The expression of PGP 9.5 protein was used to assess the quantity and mean length as well as average and total fluorescence intensity of nerve fibers. Results. An increased expression of amphiregulin and nerve growth factor as well as increase in the quantity, mean length and average and total fluorescence intensity of nerve fibers were revealed in the epidermis of psoriatic patients. Following a course of the PUVA therapy, a decrease in the PASI index and extent of itching, reduced expression of amphiregulin and nerve growth factor as well as reduced quantity, mean length and average and total fluorescence intensity of nerve fibers in the epidermis were observed. Direct correlation dependence between the extent of itching, amphiregulin and nerve growth factor expression level and quantity and length of nerve fibers in the epidermis was discovered. Direct correlation dependence between the amphiregulin and nerve growth factor expression level, and average length of nerve fibers in the epidermis was discovered. Conclusion. The itching intensity in psoriatic patients receiving the PUVA therapy is reduced due to the decreased skin expression of the nerve growth factor and amphiregulin.

About the authors

V. V. Chikin

State Research Center of Dermatovenereology and Cosmetology, Ministry of Healthcare of the Russian Federation

Author for correspondence.
Email: chikin@cnikvi.ru
Russian Federation

M. B. Zhilova

State Research Center of Dermatovenereology and Cosmetology, Ministry of Healthcare of the Russian Federation

Email: noemail@neicon.ru
Russian Federation

V. A. Smolyannikova

I.M. Sechenov First Moscow State Medical University

Email: noemail@neicon.ru
Russian Federation

M. A. Nefedova

State Research Center of Dermatovenereology and Cosmetology, Ministry of Healthcare of the Russian Federation

Email: noemail@neicon.ru
Russian Federation


  1. Yosipovitch G., Goon A., Wee J. et al. The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis. Br J Dermatol 2000; 143: 969-973.
  2. Szepietowski J.C., Reich A., Wiśnicka B. Itching in patients suffering from psoriasis. Acta Derm Venereol Croat 2002; 10 (4): 221-226.
  3. Reich A., Szepietowski J.C, Wiśnicka B., Pacan P. Does stress influence itching in psoriatic patients? Dermatol Psychosom 2003; 4: 151-155.
  4. Reich A., Orda A., Wiśnicka B., Szepietowski J.C. Plasma neuropeptides and perception of pruritus in psoriasis. Acta Derm Venereol 2007; 87: 299-304.
  5. Sampogna F., Gisondi P., Melchi C.F. et al. Prevalence of symptoms by patients with different clinical types of psoriasis. Br J Dermatol 2004; 151: 594-599.
  6. Chang S.-E., Han S.-S., Jung H.-J., Choi J.-H. Neuropeptides and their receptors in psoriatic skin in relation to pruritus. Br J Dermatol 2007; 156: 1272-1277.
  7. Amatya B., Wennersten G., Nordlind K. Patients’ perspective of pruritus in chronic plaque psoriasis: a questionnaire-based study. J Eur Acad Dermatol Venereol 2008; 22: 822-826.
  8. Bilac C., Ermertcan A.T., Bilac D.B. et al. The relationship between symptoms and patient characteristics among psoriasis patients. Ind J Dermatol Venereol Leprol 2009; 75: 551.
  9. Prignano F., Ricceri F., Pescitelli L., Lotti T. Itch in psoriasis: epidemiology, clinical aspects and treatment options. Clin Cosmet Investig Dermatol 2009; 2: 9-13.
  10. Ikoma A., Steinhoff M., Ständer S. et al. The neurobiology of itch. Nat Rev Neurosci 2006; 7 (7): 535-547.
  11. Garibyan L., Rheingold C.G., Lerner E.A. Understanding the pathophysiology of itch. Dermatol Ther 2013; 26 (2): 84-91.
  12. Shepherd A.J., Downing J.E., Miyan J.A. Without nerves, immunology remains incomplete - in vivo veritas. Immunology 2005; 116: 145-163.
  13. Raap U., Kapp A. Neuroimmunological findings in allergic skin diseases. Curr Opin Allergy Clin Immunol 2005; 5: 419-424.
  14. Buddenkotte J., Steinhoff M. Pathophysiology and therapy of pruritus in allergic and atopic diseases. Allergy 2010; 65: 805-821.
  15. Eedy D.J., Johnston C.F., Shaw C., Buchanan K.D. Neuropeptides in psoriasis: an immunocytochemical and radioimmunoasay study. J Invest Dermatol 1991; 96: 434-438.
  16. Naukkarinen A., Harvima I., Paukkonen K. et al. Immunohistochemical analysis of sensory nerves and neuropeptides, and their contacts with mast cells in developing and mature psoriatic lesions. Arch Dermatol Res 1993; 285: 341-346.
  17. Glinski W., Brodecka H., Glinska-Ferenz M., Kowalski D. Neuropeptides in psoriasis: possible role of beta-endorphin in the pathomechanism of the disease. Int J Dermatol 1994; 33: 356-360.
  18. Al’Abadie M.S., Senior H.J., Bleehen S.S., Gawkrodger D.J. Neuropeptides and general neuronal marker in psoriasis - an immunohistochemical study. Clin Exp Dermatol 1995; 20: 384-389.
  19. Chan J., Smoller B.R., Raychauduri S.P. et al. Intraepidermal nerve fiber expression of calcitonin gene-related peptide, vasoactive intestinal peptide and substance P in psoriasis. Arch Dermatol Res 1997; 289: 611-616.
  20. Jiang W.-Y., Raydchaudhuri S.P., Farber E.M. Double-labelled immunofluorescence study of cutaneous nerves in psoriasis. Int J Dermatol 1998; 37: 572-574.
  21. Staniek V., Doutremepuich J., Schmitt D. et al. Expression of substance P receptors in normal and psoriatic skin. Pathobiology 1999; 67: 51-54.
  22. He Y., Ding G., Wang X. et al. Calcitonin gene-related peptide in Langerhans cells in psoriatic plaque lesions. Chin Med J 2000; 113: 747-751.
  23. Saraceno R., Kleyn C.E., Terenghi G., Griffiths C.E. The role of neuropeptides in psoriasis. Br J Dermatol 2006; 155: 876-882.
  24. Ikoma A., Rukwied R., Ständer S. et al. Neuronal sensitization for histamine-induced itch in lesional skin of patients with atopic dermatitis. Arch Dermatol 2003; 139: 1455-1458.
  25. Ikoma A., Handwerker H., Miyachi Y., Schmelz M. Electrically evoked itch in humans. Pain 2005; 113: 148-154.
  26. van Laarhoven A.I., Kraaimaat F.W., Wilder-Smith O.H. et al. Sensitivity to itch and pain in patients with psoriasis and rheumatoid arthritis. Exp Dermatol 2013; 22: 530-534.
  27. Han L., Dong X. Itch mechanisms and circuits. Annu Rev Biophys 2014; 43: 331-355.
  28. Tominaga M., Takamori K. An update on peripheral mechanisms and treatments of itch. Biol Pharm Bull 2013; 36 (8): 1241-1247.
  29. Crowley C., Spencer S.D., Nishimura M.C. et al. Mice lacking nerve growth factor display perinatal loss of sensory and sympathetic neurons yet develop basal forebrain cholinergic neurons. Cell 1994; 76 (6): 1001-1011.
  30. Albers K.M., Wright D.E. Davis B.M. Overexpression of nerve growth factor in epidermis of transegenic mice causes hypertrophy of the peripheral nervous system. J Neurosci 1994; 14, 1422-1432.
  31. Kimura H., Schubert D. Schwannoma-derived growth factor promotes the neuronal differentiation and survival of PC12 cells. J Cell Biol 1992; 116 (3): 777-783.
  32. Nilsson A., Kanje M. Amphiregulin acts as an autocrine survival factor for adult sensory neurons. Neuroreport 2005; 16 (3): 213-218.
  33. Dontchev V.D., Letourneau P.C. Nerve growth factor and semaphorin 3A signaling pathways interact in regulating sensory neuronal growth cone motility. J Neurosci 2002; 22 (15): 6659-6669.
  34. Tominaga M., Kamo A., Tengara S. et al. In vitro model for penetration of sensory nerve fibres on a Matrigel basement membrane: implications for possible application to intractable pruritus. Br J Dermatol. 2009; 161 (5): 1028-1037.
  35. Jekler J., Larkö O. UVB phototherapy of atopic dermatitis. Br J Dermatol 1988; 119: 697-705.
  36. Jekler J., Larkö O. UVA-UVB versus UVB phototherapy for atopic dermatitis: A paired comparison study. J Am Acad Dermatol 1990; 22: 49-53.
  37. von Kobyletzki G., Pieck C., Hoffmann K. et al. Medium-dose UVA1 cold-light phototherapy in the treatment of severe atopic dermatitis. J Am Acad Dermatol 1999; 41 (6): 931-937.
  38. Krutmann J., Diepgen T.L., Luger T.A. et al. Highdose UVA1 therapy for atopic dermatitis: results of a multicenter trial. J Am Acad Dermatol 1998; 38 (4): 589-593.
  39. Reynolds N.J., Franklin V., Gray J.C. et al. Narrowband ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: a randomised controlled trial. Lancet 2001; 357 (9273): 2012-2016.
  40. Clayton T.H., Clark S.M., Turner D., Goulden V. The treatment of severe atopic dermatitis in childhood with narrowband ultraviolet B phototherapy. Clin Exp Dermatol 2007; 32 (1): 28-33.
  41. Karvonen J., Hannuksela M. Long term results of topical trioxsalen PUVA in lichen planus and nodular prurigo. Acta Derm Venereol Suppl [Stockh]. 1985; 120: 53-55.
  42. Vaatainen N., Hannuksela M., Karvonen J. Local photochemotherapy in nodular prurigo. Acta Derm Venereol. 1979; 59: 544-547.
  43. Gambichler T., Hyun J., Sommer A. et al. A randomised controlled trial on photo(chemo)therapy of subacute prurigo. Clin Exp Dermatol 2006; 31: 348-353.
  44. Pothiawala S.Z., Baldwin B.T., Cherpelis B.S. et al. The role of phototherapy in cutaneous T-cell lymphoma. J Drugs Dermatol 2010; 9: 764-772.
  45. Kaptanoglu A.F., Oskay T. Ultraviolet B treatment for pruritus in Hodgkin’s lymphoma. J Eur Academy Dermatol Venereol 2003; 17: 489-490.
  46. Baldo A., Sammarco E., Plaitano R. et al. Narrowband (TL-01) ultraviolet B phototherapy for pruritus in polycythaemia vera. Br J Dermatol. 2002; 147: 979-981.
  47. Lim H.W., Vallurupalli S., Meola T. et al. UVB phototherapy is an effective treatment for pruritus in patients infected with HIV. J Am Acad Dermatol. 1997; 37: 414-417.
  48. Gilchrest B.A., Rowe J.W., Brown R.S. et al. Ultraviolet phototherapy of uremic pruritus. Long-term results and possible mechanism of action. Ann Intern Med 1979; 91: 17-21.
  49. Kamo A., Tominaga M., Tengara S. et al. Inhibitory effects of UV-based therapy on dry skin-inducible nerve growth in acetone-treated mice. J Dermatol Sci 2011; 62 (2): 91-97.
  50. Tominaga M., Tengara S., Kamo A. et al. Psoralen-ultraviolet A therapy alters epidermal Sema3A and NGF levels and modulates epidermal innervation in atopic dermatitis. J Dermatol Sci 2009; 55: 40-46.
  51. Wallengren J., Sundler F. Phototherapy reduces the number of epidermal and CGRP-positive dermal nerve fibres. Acta Derm Venereol 2004; 84 (2): 111-115.
  52. Chen X., Yang M., Cheng Y. et al. Narrow-band ultraviolet B phototherapy versus broad-band ultraviolet B or psoralen-ultraviolet A photochemotherapy for psoriasis. Cochrane Database Syst Rev 2013 Oct 23;10:CD009481.
  53. Racz E., Prens E.P. Phototherapy and photochemotherapy for psoriasis. Dermatol Clin 2015; 33: 79-89.
  54. Katunina O.R., Chikin V.V., Znamenskaya L.F., Inoyatova L.A. Role of neuromediators in the development of skin irritation in patients with atopic dermatitis. Vestnik Dermatologii i Venerologii 2013; 5: 91-101. [Катунина О.Р., Чикин В.В., Знаменская Л.Ф., Иноятова Л.А. Роль нейромедиаторов в развитии воспаления в коже больных атопическим дерматитом. Вестн дерматол венерол 2013; (5): 91-101.]

Copyright (c) 2015 Chikin V.V., Zhilova M.B., Smolyannikova V.A., Nefedova M.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 60448 от 30.12.2014.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies